SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    United Network for Organ Sharing Data Report: Liver Kaplan-Meier Graft Survival Rates for Transplants Performed 1996-2001. Available at: http://www.optn.org. Accessed: February 2, 2004.
  • 2
    Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery 2002; 132: 775780.
  • 3
    Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901906.
  • 4
    Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delrivere LD, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004; 77: 9399.
  • 5
    O'Grady JG, Burroughs, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360: 11191125.
  • 6
    Mühlbacher F.; European Liver Transplantation Tacrolimus vs Cyclosporin Microemulsion Study Group. Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. Transplant Proc 2001; 33: 13391340.
  • 7
    Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et al. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 8
    Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation 2002; 73: 953959.
  • 9
    Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004; 10: 577583.
  • 10
    Yantorno SE, Varela EB, Raffa SR, Descalzi VI, Gomez Carretero ML, Pirola DA, et al. How common is delayed cyclosporine absorption following liver transplantation? Liver Transpl 2005; 11: 16773.
  • 11
    Watashi K, Hijakata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 12821288.
  • 12
    Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313: 4247.
  • 13
    Maniŕe T, Ethier C, Raymond VA, Andre A, Bilodeau M. Evaluation of the effect of immunosuppressive agents on hepatitis C: cyclosporine reduces viral replication in the replicon model [abstract]. Transplantation 2004; 78(suppl 1): 1314.
  • 14
    Sheiner PA, Schwartz ME, Mor E, Schulager LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 3034.
  • 15
    Johnson MW, Washburn WK, Freeman RB, Fitzmaurice SE, Dienstag J, Basgoz N, et al. Hepatitis C viral infection in liver transplantation. Arch Surg 1996; 131: 284291.
  • 16
    Paik SW, Tan HP, Klein AS, Boitnott JK, Thulavath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002; 47: 450455.
  • 17
    Duvoux C, Mennecier D, Pageaux G, Conti F, Roudot-Thoraval F, Dhumeaux D. Immunosuppression with tacrolimus an absence of antihypertensive therapy are associated with fibrosis progression after hepatitis C virus (HCV) graft reinfection. International Society of Transplantation Congress 2002 [abstract 2652]. Transplantation 2002; 74(suppl).
  • 18
    Hunt J, Gordon FD, Lewis WD, et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001; 7: 10561063.
  • 19
    Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 20
    Ghobrial RM, Farmer DG, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 6: 824833.
  • 21
    Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77: 226231.
  • 22
    Ericzon B, Groth C, Bismuth H, Calne R, McMaster P, Neuhaus P, et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. Transplant Int 1994; 7(suppl): S11S14.
  • 23
    Lohmann T, List C, Lamesch P, Kohlhaw K, Wenzke M, Schwarz C, et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunosuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108: 347352.
  • 24
    Prasad GV, Kim SJ, Huang M, Kohlhaw K, Zaltzman JS, Fenton SS, et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). Am J Transplant 2004; 4: 18971903.